What are the medical insurance reimbursement conditions for Vebreltinib?
Vebreltinib (vebreltinib), as a MET inhibitor independently developed in China, quickly entered the national medical insurance directory after being launched in the country, reflecting the high degree of policy support for domestically produced innovative drugs. The medical insurance reimbursement conditions are particularly critical for patients, as they directly determine the accessibility and economic burden of treatment.

According to the latest medical insurance directory, the medical insurance reimbursement of bricitinib is mainly for the following two types of patients. The first category is patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping. After these patients fail to receive standard treatments, they can use britinib under the guidance of a doctor and reduce the cost of medication through medical insurance reimbursement. The second category is patients with IDH-mutant astrocytoma (WHO grade IV) with PTPRZ1-MET fusion gene who have failed previous treatment, or adult patients with glioblastoma who have a history of low-grade glioblastoma. The treatment options for these patients are limited, and the coverage of bricitinib by medical insurance will undoubtedly improve the affordability of their treatment.
In terms of drug specifications and prices, bricitinib is currently available on the market in the form of100mg*60 capsules/box, with the price of each box being approximately RMB 7,000. After being included in medical insurance, the actual amount paid by the patient will vary depending on factors such as regional differences, out-of-pocket ratio, and medical insurance reimbursement ceiling. Taking most regions as an example, bricitinib is a Class B drug, and the reimbursement ratio by medical insurance is between 50% and 70%, which means that patients’ out-of-pocket expenses are much lower than when they are not reimbursed.
In addition, medical insurance reimbursement conditions usually require that patients must undergo genetic testing to confirm the presence of corresponding molecular characteristics before they meet the medication and reimbursement standards. This not only ensures the precise use of drugs, but also avoids waste of resources. When applying for reimbursement, patients need to provide genetic testing reports, pathological diagnosis data, doctor's prescriptions and other documents. They must be reviewed by the hospital's medical insurance office or relevant departments before they can enjoy the reimbursement policy.
Reference materials:https://www.asymbio.com.cn/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)